Compare LSE & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSE | ONCY |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.5M | 80.5M |
| IPO Year | 2023 | 2002 |
| Metric | LSE | ONCY |
|---|---|---|
| Price | $4.59 | $0.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.16 |
| AVG Volume (30 Days) | 3.7K | ★ 1.2M |
| Earning Date | 09-14-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $61.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.20 | $0.44 |
| 52 Week High | $6.98 | $1.32 |
| Indicator | LSE | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 44.56 | 31.96 |
| Support Level | $4.47 | $0.44 |
| Resistance Level | $5.04 | $0.89 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 33.06 | 35.23 |
Leishen Energy Holding Co Ltd is a provider of clean-energy equipment and integrated solutions to the oil and gas industry, with a commitment to providing customers with high-performance, safe, and cost-effective energy solutions. The company's business segments include clean-energy equipment, oil and gas engineering technical services, new energy production and operation, and digitalization and integration equipment. A majority of its revenue is generated from the clean-energy equipment segment, which supplies various equipment, such as reciprocating compressor units, expansion units, wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment, and polymer flexible composite pipes.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.